SCHEMBL17824637

SCHEMBL17824637

Cn1c(=O)[nH]c2ccc(S(=O)(=O)Cl)cc2c1=O

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 8/20 0.61
ADORA3 P0DMS8 2/20 0.53
ADORA2B P29275 2/20 0.53
ADORA2A P29274 1/20 0.53
ADORA1 P30542 1/20 0.53
BRD4 O60885 1/20 0.46
CA12 O43570 3/20 0.41
CA9 Q16790 3/20 0.41
PIK3CG P48736 1/20 0.39
CMA1 P23946 1/20 0.39
MAPT P10636 1/20 0.38
FEN1 P39748 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638486 0.86 PARG (0.62) PARGADORA3ADORA2BADORA2AADORA1
SCHEMBL6390624 0.85 PARG (0.61) PARGADORA3ADORA2BADORA2AADORA1
Hydrochloric Acid SCHEMBL28174304 0.84 PARG (0.60) PARGADORA3ADORA2BADORA2AADORA1
SCHEMBL17825030 0.81 PARG (0.63) PARG
SCHEMBL9919007 0.78 CA9 (0.66) PARGADORA3ADORA2BADORA2AADORA1
SCHEMBL17825151 0.76 PARG (1.00) PARG
SCHEMBL17825124 0.76 PARG (0.61) PARGPIK3CGRXFP1
SCHEMBL8215674 0.76 ADORA3 (0.61) PARGADORA3ADORA2BADORA2AADORA1
SCHEMBL5355203 0.74 CA12 (0.66) PARGADORA3ADORA2BADORA2AADORA1
SCHEMBL9923029 0.74 ADORA3 (0.59) PARGADORA3ADORA2BADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 US disclosed
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 US disclosed
EP-3230273-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG Cancer Research Technology Ltd (GB) 2017-10-18 EP disclosed
CN-107207467-A 2, 4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG 癌症研究科技有限公司 2017-09-26 CN disclosed
WO-2016092326-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-16 WO disclosed
WO-2016092326-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG PARG, PARP15, PARP12 PARG 1/4885ADORA3 455/4885ADORA2B 209/4885
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG PARG, PARP15, PARP12 PARG 1/4885ADORA3 455/4885ADORA2B 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.